• ISSN 16748301
  • CN 32-1810/R
Volume 32 Issue 6
Jun.  2018
Article Contents

Citation:

Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer

  • Received Date: 2017-06-20
    Accepted Date: 2018-05-21

    Fund Project: This work was supported by the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (grant number 17KJD330002) the Science and Technology Development Fund of Nanjing Medical University (grant number 2017NJMUZD141) and the Science and Technology Development Fund of Kangda College of Nanjing Medical University (grant number KD2016KYJJZD007, KD2016KYJJZD008). The funding agencies had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.

  • Identifying sensitive and specific biomarkers for early detection of cancer is immensely imperative for early diagnosis and treatment and better clinical outcome of cancer patients. This study aimed to construct a specific DNA methylation pattern of cancer suppressor genes and explore the feasibility of applying cell-free DNA based methylation as a biomarker for early diagnosis of esophageal squamous cell carcinoma (ESCC). We recruited early stage ESCC patients from Yangzhong County, China. The Illumina Infinium 450K Methylation BeadChip was used to onstruct a genome-wide DNA methylation profile. Then, differentiated genes were selected for the validation study using the Sequenom MassARRAY platform. The frequency of methylation was compared between cancer tissues, matched cell-free DNAs and normal controls. The specific methylation profiles were constructed, and the sensitivity and specificity were calculated. Seven CG sites in three genes CASZ1, CDH13 and ING2 were significantly hypermethylated in ESCC as compared with normal controls. A significant correlation was found between the methylation of DNA extracted from cancer tissues and matched plasma cell-free DNA, either for individual CG site or for cumulative methylation analysis. The sensitivity and specificity reached 100% at an appropriate cut-point using these specific methylation biomarkers. This study revealed that aberrant DNA methylation is a promising biomarker for molecular diagnosis of esophageal cancer. Hypermethylation of CASZ1, CDH13 and ING2 detected in plasma cell-free DNA can be applied as a potential noninvasive biomarker for diagnosis of esophageal cancer.
  • 加载中
  • 加载中

Figures(1)

Article Metrics

Article views(506) PDF downloads(37) Cited by()

Related
Proportional views
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer

  • 1. Department of Public Health and Preventive Medicine, Kangda College of Nanjing Medical University, Lianyungang, Jiangsu 222000, China
  • 2. Department of Pathology, The First People's Hospital of Lianyungang, Lianyungang, Jiangsu 222000, China
  • 3. Department of Clinical Medicine, Kangda College of Nanjing Medical University, Lianyungang, Jiangsu 222000, China
  • 4. Department of Epidemiology, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China
  • 5. Department of Epidemiology, Department of Social Medicine and Health Education, The Innovation Center for Social Risk Governance in Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu 211166, China
Fund Project:  This work was supported by the Natural Science Foundation of the Jiangsu Higher Education Institutions of China (grant number 17KJD330002) the Science and Technology Development Fund of Nanjing Medical University (grant number 2017NJMUZD141) and the Science and Technology Development Fund of Kangda College of Nanjing Medical University (grant number KD2016KYJJZD007, KD2016KYJJZD008). The funding agencies had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.

Abstract: Identifying sensitive and specific biomarkers for early detection of cancer is immensely imperative for early diagnosis and treatment and better clinical outcome of cancer patients. This study aimed to construct a specific DNA methylation pattern of cancer suppressor genes and explore the feasibility of applying cell-free DNA based methylation as a biomarker for early diagnosis of esophageal squamous cell carcinoma (ESCC). We recruited early stage ESCC patients from Yangzhong County, China. The Illumina Infinium 450K Methylation BeadChip was used to onstruct a genome-wide DNA methylation profile. Then, differentiated genes were selected for the validation study using the Sequenom MassARRAY platform. The frequency of methylation was compared between cancer tissues, matched cell-free DNAs and normal controls. The specific methylation profiles were constructed, and the sensitivity and specificity were calculated. Seven CG sites in three genes CASZ1, CDH13 and ING2 were significantly hypermethylated in ESCC as compared with normal controls. A significant correlation was found between the methylation of DNA extracted from cancer tissues and matched plasma cell-free DNA, either for individual CG site or for cumulative methylation analysis. The sensitivity and specificity reached 100% at an appropriate cut-point using these specific methylation biomarkers. This study revealed that aberrant DNA methylation is a promising biomarker for molecular diagnosis of esophageal cancer. Hypermethylation of CASZ1, CDH13 and ING2 detected in plasma cell-free DNA can be applied as a potential noninvasive biomarker for diagnosis of esophageal cancer.

    HTML

Catalog

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return